The DOI matches its Crossref record; 149 of the 156 references it cites were found in a registry or an index.
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Open accessAbstract
Nanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the treatment efficacy while reducing detrimental side effects to normal tissues. Cancer drug resistance is a complicated process that involves multiple mechanisms. Here we discuss the major forms of drug resistance and the new possibilities that nanomedicines offer to overcome these treatment obstacles. Novel nanomedicines that have a high ability for flexible, fast drug design and production based on tumor genetic profiles can be created making drug selection for personal patient treatment much more intensive and effective. This review aims to demonstrate the advantage of the young medical science field, nanomedicine, for overcoming cancer drug resistance. With the advanced design and alternative mechanisms of drug delivery known for different nanodrugs including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles, overcoming various forms of multi-drug resistance looks promising and opens new horizons for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary rationale of using a suitable drug delivery system is its ability to ensure a higher and longer duration of drug bioavailability and thereby enhanced therapeutic efficacy.14,15”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“from normal stem cells versus progenitor cells, is still not clear and may vary from tumor to tumor or by tumor type [48].”
BackgroundSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Prospective identification of tumorigenic breast cancer cells
Al‐Hajj, M., Wicha, M. S., Benito‐Hernández, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,579 · cited 1×
“Tumor initiating cells were later isolated in breast carcinomas, and it was shown that only a subset of cells could be serially passaged and gave rise to both phenotypically identical and diverse cells consistent with those found in the initial tumor [40].”
ResultStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 3×
“Additional stem cell markers including CD44 [38,121] and CD133 [121] have been associated with drug resistance and may serve as potential targets for future nanodrugs to eliminate CSCs and prevent recurrence.”
BackgroundEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 1×
“Inframe deletions in exon 19 and single missense mutations account for approximately 90% of the EGFR mutations, and result in an increased sensitivity to both small molecule inhibitors, gefitinib and erlotinib [52-54].”
BackgroundNanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“It is accepted at the current stage of cancer biology that tumors at the same clinical grade and histological status are genetically heterogeneous and contain subclonal populations [33].”
BackgroundIdentification of human brain tumour initiating cells
Singh, S. K., Hawkins, C. E., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,564 · cited 1×
“Cancer stem cells have also been isolated from medulloblastoma, glioblastoma [41], ependymoma [42], colon cancer [43,44], chronic and acute myeloid leukemia [45], pancreatic cancer [46], and head and neck squamous cell carcinomas [47].”
BackgroundBonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197 · cited 1×
“showed that only a very small subset of cells that were CD34+CD38− had the ability to cause AML in NOD/SCID mice, indicating that subpopulations of cells had differential abilities to proliferate and transfer disease [39].”
Background
Flagged first, then by citations
7 of the 156 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
“To date, there has been limited success in overcoming drug resistance in cancers through the use of novel small molecule chemotherapeutics (5, 6), or nanoformulations of existing chemotherapeutics (7-9).”
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,214
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
“The primary rationale of using a suitable drug delivery system is its ability to ensure a higher and longer duration of drug bioavailability and thereby enhanced therapeutic efficacy.(14,15) Various materials with different structural forms are conjugated with drugs to prepare nano drug delivery systems.”
BackgroundEmran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Emerging roles of lncRNA in cancer and therapeutic opportunities.
Jiang, M., Ni, J., Cui, W., Wang, B., & Zhuo, W. (2019) · PubMed · Cited by 502
Recent progress in nanomedicine for enhanced cancer chemotherapy
Wei, G., Wang, Y., Yang, G. Y., Wang, Y., & Ju, R. (2021) · Theranostics · doi:10.7150/thno.57828 · Cited by 484
“Therefore, overcoming the P-gp-mediated MDR mechanism is one of most widely employed strategies to improve the effect of chemotherapeutics on MDR tumors [85].”
Advances in redox-responsive drug delivery systems of tumor microenvironment
Guo, X., Cheng, Y., Zhao, X., Luo, Y., Chen, J., & Yuan, W.-E. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0398-2 · Cited by 459
“ATNDDS can improve the solubility and stability of drugs, enhance the targeting ability, reduce potential toxicity, achieve the co-delivery of drugs and genes, and realize the collaborative treatment [3].”
BackgroundSynthetic polypeptides: from polymer design to supramolecular assembly and biomedical application
Song, Z., Han, Z., Lv, S., Chen, C., Chen, L., Yin, L., & Cheng, J. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00460e · Cited by 409
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Qin, T., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 406
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 340
Nanotechnology-based antiviral therapeutics
Chakravarty, M., & Vora, A. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00818-0 · Cited by 348
Advanced drug delivery applications of layered double hydroxide
Shirin, V. K. A., Sankar, R., Johnson, A. P., Gangadharappa, H. V., & Pramod, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.041 · Cited by 319
Bottom-Up Synthesis of Metal-Ion-Doped WS2 Nanoflakes for Cancer Theranostics
Cheng, L., Yuan, C., Shen, S., Yi, X., Gong, H., Yang, K., & Liu, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b04606 · Cited by 302
“treatment, the tumor tissues in group (1), (3), (5), and (6) were dissected to make paraffin section for”
MethodThe role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 313
“Tumor microenvironment has been considered to be of great importance in various therapeutic attempts including one investigating the use of nanomedicine [124, 125].”
BackgroundMangal, S., Gao, W., Li, T., & Zhou, Q. T. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.34 · Cited by 295
The Promise of Nanotechnology in Personalized Medicine
Alghamdi, M. A., Fallica, A. N., Virzì, N. F., Kesharwani, P., Pittalà, V., & Greish, K. F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050673 · Cited by 324
“Furthermore, cells who acquire resistance to chemotherapeutic agents usually become resistant also to drugs belonging to different chemical classes or to drugs acting with a different mechanism of action, globally worsening the MDR phenomena [28].”
Zhong, Y., Zhang, J., Cheng, R., Deng, C., Meng, F., Xie, F., & Zhong, Z. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.012 · Cited by 285
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 288
He, C., Liu, D., & Lin, W. (2015) · ACS Nano · doi:10.1021/nn506963h · Cited by 274
“Combination therapy, such as the combination of chemotherapy and PDT, can promote synergism between different treatment modalities, overcome drug resistance through distinct mechanisms of actions, and enhance the anticancer efficacy.(56,57) To further enhance the potency of the NCP platform, we incorporated the effici…”
MethodReview of Natural Compounds for Potential Skin Cancer Treatment
Chinembiri, T. N., Plessis, D., Gerber, M., Hamman, J. H., & du Plessis, J. (2014) · Molecules · doi:10.3390/molecules190811679 · Cited by 276
“Various strategies have been attempted to overcome drug resistance, such as the use of nanoparticles, liposomes and micellar drug delivery vehicles, with some reported successes [11].”
BackgroundZhu, L., Zhou, Z., Mao, H. Z., & Yang, L. P. H. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0316 · Cited by 268
Synergistic nanomedicine by combined gene and photothermal therapy
Kim, J., Kim, J., Jeong, C., & Kim, W. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.018 · Cited by 264
Du, X. C., Li, X., Xiong, L., Zhang, X., Kleitz, F., & Qiao, S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.019 · Cited by 266
Chitosan nanopolymers: An overview of drug delivery against cancer
Shanmuganathan, R., Edison, T. N. J. I., LewisOscar, F., Kumar, P., Shanmugam, S., & Pugazhendhi, A. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.02.060 · Cited by 248
Liu, D., Zhang, H., Fontana, F., Hirvonen, J. J., & Santos, H. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.003 · Cited by 241
“, gold, porous silica, porous silicon, carbon nanotubes, and fullerenes) [11].”
Advances of medical nanorobots for future cancer treatments
Kong, X., Gao, P., Wang, J., Fang, Y., & Hwang, K. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01463-z · Cited by 260
“The MDR phenomenon refers to the development of resistance of cancer cells, after repeated treatment, not only to the specific chemotherapeutic agent used, but also to other cytotoxic agents with different chemical structures or mechanisms of action, resulting in cross-resistance [270, 271].”
BackgroundThe landscape of nanoparticle-based siRNA delivery and therapeutic development
Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.005 · Cited by 230
Beretta, G. L., Cassinelli, G., Pennati, M., Zuco, V., & Gatti, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.062 · Cited by 239
“Generally, cancer drug resistance is divided in three major types on the base of different aspects [8]: i) kinetic, involving tumors possessing slow growth rate.”
BackgroundStimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance
Zhou, L., Wang, H., & Li, Y. (2018) · Theranostics · doi:10.7150/thno.22679 · Cited by 232
“Multiple mechanisms of tumor resistance have been explored [5, 7, 8], which can be grouped into: a) overexpression of ATP-binding cassette pumps (e.”
BackgroundMulticellular Tumor Spheroids (MCTS) as a 3D In Vitro Evaluation Tool of Nanoparticles
Lu, H., & Stenzel, M. H. (2018) · Small · doi:10.1002/smll.201702858 · Cited by 234
Application of polydopamine in tumor targeted drug delivery system and its drug release behavior
Wang, Z., Duan, Y., & Duan, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.009 · Cited by 235
Jiang, J., Wang, K., Chen, Y., Chen, H., Nice, E. C., & Huang, C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.36 · Cited by 233
Durfee, P. N., Lin, Y.-S., Dunphy, D. R., Muñiz, A. J., Butler, K. S., Humphrey, K. R., Lokke, A. J., Agola, J. O., Chou, S. S., Chen, I.-M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02819 · Cited by 219
Wani, W. A., Prashar, S., Shreaz, S., & Gómez‐Ruiz, S. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.01.001 · Cited by 221
Intracellular Self‐Assembly of Taxol Nanoparticles for Overcoming Multidrug Resistance
Yuan, Y., Wang, L., Du, W., Ding, Z., Zhang, J., Han, T., An, L., Zhang, H., & Liang, G. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504329 · Cited by 210
Near-infrared-light responsive nanoscale drug delivery systems for cancer treatment
Yang, G., Liu, J., Wu, Y., Feng, L., & Liu, Z. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.04.004 · Cited by 207
Liu, S., Pan, J., Liu, J., Ma, Y., Qiu, F., Mei, L., Zeng, X., & Pan, G. (2018) · Small · doi:10.1002/smll.201703968 · Cited by 200
Liu, H., Yang, Y., Liu, Y., Pan, J., Wang, J., Man, F., Zhang, W., & Liu, G. (2020) · Advanced Science · doi:10.1002/advs.201903129 · Cited by 200
Gu, W., Meng, F., Haag, R., & Zhong, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.003 · Cited by 198
Kim, J., Yung, B. C., Kim, W. J., & Chen, X. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.026 · Cited by 191
Xu, Y., Xiong, J., Sun, X., & Gao, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.001 · Cited by 188
Deep Insight of Design, Mechanism, and Cancer Theranostic Strategy of Nanozymes
Yang, L. G., Dong, S., Gai, S., Yang, D., Ding, H., Feng, L., Yang, G., Rehman, Z., & Yang, P. (2023) · Nano-Micro Letters · doi:10.1007/s40820-023-01224-0 · Cited by 191
Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases
Chowdhury, A., Kunjiappan, S., Theivendren, P., Somasundaram, B., & Bhattacharjee, C. (2017) · International nano letters. · doi:10.1007/s40089-017-0208-0 · Cited by 189
“It can be utilize as a potential vehicle to deliver micromolecules such as proteins, DNA, or RNA [80].”
BackgroundInfluentialMetastatic disease in head & neck oncology
Pisani, P., Airoldi, M., Allais, A., Valletti, P. A., Battista, M., Benazzo, M., Briatore, R., Cacciola, S., Cocuzza, S. G., Colombo, A., et al. (2020) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-suppl.1-40-2020 · Cited by 197
Design of liposomal formulations for cell targeting
Nogueira, E., Gomes, A. C., Preto, A., & Cavaco-Paulo, A. M. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.09.034 · Cited by 171
Li, W.-Q., Wang, Z., Hao, S., He, H., Wan, Y., Zhu, C., Sun, L.-P., Cheng, G., & Zheng, S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01540 · Cited by 173
Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer
Sonali, Viswanadh, M. K., Singh, R. P., Agrawal, P., Mehata, A. K., Pawde, D. M., Narendra, N., Sonkar, R., & Muthu, M. S. (2017) · Nanotheranostics · doi:10.7150/ntno.21638 · Cited by 170
“The National Institute of Health (NIH) in the USA described nanomedicine as utilization of nanotechnology in the diagnosis, therapy with simultaneous monitoring on biological systems [26].”
BackgroundYousuf, I., Bashir, M., Arjmand, F., & Tabassum, S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214104 · Cited by 167
Redox-Responsive Drug Delivery Systems: A Chemical Perspective
Abed, H., Abuwatfa, W. H., & Husseini, G. A. (2022) · Nanomaterials · doi:10.3390/nano12183183 · Cited by 168
“Although widely used, conventional methods like chemotherapy are limited due to their toxic side effects, low specificity, and resistance to the treatment, whether inherently present or developed later after successful initial treatments [3].”
BackgroundOne‐Pot Synthesis of DOX@Covalent Organic Framework with Enhanced Chemotherapeutic Efficacy
Liu, S., Hu, C., Liu, Y., et al. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201806242 · Cited by 155
Zhang, B., Luo, Z. Y., Liu, J., Ding, X., Li, J., & Cai, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.037 · Cited by 152
Peng, Z., & Kopec̆ek, J. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b00922 · Cited by 151
Near-infrared photoresponsive drug delivery nanosystems for cancer photo-chemotherapy
Wang, X., Xuan, Z., Zhu, X., Sun, H., Li, J., & Xie, Z. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00668-5 · Cited by 153
Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance
Najafi, M., Farhood, B., Mortezaee, K., Kharazinejad, E., Majidpoor, J., & Ahadi, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03080-1 · Cited by 151
Combination antitumor therapy with targeted dual-nanomedicines
Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 139
“It is worth noting that nanoconjugates or other nanomedicines, especially ligand modified nanomedicines, might evade the capture of MDR transporter [152].”
BackgroundConde, J., Oliva, N., & Artzi, N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421229112 · Cited by 139
Challenges and strategies in drug delivery systems for treatment of pulmonary infections
Ho, D., Nichols, B. L. B., Edgar, K. J., Murgia, X., Loretz, B., & Lehr, C. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.09.002 · Cited by 142
The past, present, and future of breast cancer models for nanomedicine development
Boix-Montesinos, P., Soriano‐Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.018 · Cited by 146
Nanomedicine-mediated cancer stem cell therapy
Shen, S., Xia, J., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.037 · Cited by 132
“Increasing evidence indicates that properly designed nanomedicines provide promise for overcoming MDR predominantly mediated by ATP-driven pumps, which is a key trait and intractable obstacle of CSCs [120].”
BackgroundLi, S., Saw, P. E., Lin, C., Nie, Y., Tao, W., Farokhzad, O. C., Zhang, L., & Xu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119760 · Cited by 133
Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics
Akhter, M., Rizwanullah, M., Ahmad, J., Ahsan, M., Mujtaba, M. A., & Amin, S. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1366333 · Cited by 114
“Novel nanomedicines offers compromising drug design and fabricating formulations in fast track based on cancer homo or heterogenic profile and make treatment mode quite effective and rationale [9].”
BackgroundPoly(ethylene glycol) alternatives in biomedical applications
Yao, X., Qi, C., Sun, C., Huo, F., & Jiang, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101738 · Cited by 131
Tumor therapy: targeted drug delivery systems
Dai, L., Liu, J., Luo, Z. Y., Li, M., & Cai, K. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01743f · Cited by 128
Wang, G., Wang, Z., Li, C., Duan, G., Wang, K., Li, Q., & Tao, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.137 · Cited by 127
He, C., Poon, C. J., Chan, C., Yamada, S. D., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b02486 · Cited by 126
Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Ibrahim, M., Sabouni, R., & Husseini, G. A. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160926151216 · Cited by 126
“Over the past two decades and after understanding the nature and the interaction between anti-cancer drugs and the tumors, nanotechnology applications (including the development of nanocarriers) have been extensively researched to increase the specificity of anti-neoplastic agents towards cancerous tissues [13, 23-26].”
BackgroundNanoparticle drug delivery systems for synergistic delivery of tumor therapy
Chen, D., Liu, X., Lu, X., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111991 · Cited by 142
“These biological properties give nanoparticles several advantages, such as tumor-targeted delivery, decreased systemic side effects, prolonged plasma circulation, etc (Markman et al., 2013; Wei et al., 2021).”
BackgroundMedicinal chemistry of acridine and its analogues
Prasher, P., & Sharma, M. (2018) · MedChemComm · doi:10.1039/c8md00384j · Cited by 125
Luan, F., He, X., & Zeng, N. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13339 · Cited by 124
“Cancer is one of the most devastating and haunting diseases posing a severe threat to millions of people’s life and health.([1]) The disease is also a prominent cause of death, with increasing incidence and mortality rates worldwide.”
BackgroundSu, Y., Hu, Y., Du, Y., Huang, X., He, J., You, J., Yuan, H., & Hu, F. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500710x · Cited by 120
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Chen, D., Gu, X., Nurzat, Y., Xu, L., Li, X., Wu, L., Jiao, H., Gao, P., Zhu, X., Yan, D., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02089-6 · Cited by 127
“Furthermore, nanomedicine-based RNA modification has greatly expanded, improving drug bioavailability, tumor targeting, and intracellular release efficiency, thus enhancing therapeutic outcomes while mitigating adverse effects [381–386].”
BackgroundNanoparticles for imaging and treatment of metastatic breast cancer
Mu, Q., Wang, H., & Zhang, M. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1208650 · Cited by 119
“and significantly reduce effective dose, and thus toxicity of drugs [39].”
BackgroundRajan, A., Rajan, A. R., & Philip, D. (2016) · OpenNano · doi:10.1016/j.onano.2016.11.002 · Cited by 118
Wei, Y., Gu, X., Sun, Y., Meng, F., Storm, G., & Zhong, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.012 · Cited by 117
Mamaeva, V., Niemi, R., Beck, M., Özliseli, E., Desai, D., Landor, S. K.-J., Grönroos, T. J., Kronqvist, P., Pettersen, I. K. N., McCormack, E., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.42 · Cited by 115
Li, H., Yuan, X., Yan, D., Li, D., Guan, F., Yang, D., Wang, H., Liu, X., & Yang, B. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478917 · Cited by 113
Recent applications and strategies in nanotechnology for lung diseases
Zhong, W., Zhang, X., Zeng, Y., Lin, D., & Wu, J. (2021) · Nano Research · doi:10.1007/s12274-020-3180-3 · Cited by 116
Hydrogen Sulfide: An Emerging Precision Strategy for Gas Therapy
Ding, H., Chang, J., He, F., Gai, S., & Yang, P. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101984 · Cited by 113
Borophene-based biomedical applications: Status and future challenges
Duo, Y., Xie, Z., Wang, L., et al. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213549 · Cited by 111
Yap, K. M., Sekar, M., Fuloria, S., Wu, Y. S., Gan, S. H., Rani, N. N. I. M., Subramaniyan, V., Kokare, C., Lum, P. T., Begum, M. Y., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s328135 · Cited by 123
“The Major Classes of Nano-Based Drug Delivery Systems Evaluated for Breast Cancer Therapy The use of NDDSs for cancer therapy is promising, as NDDSs have demonstrated potentials in enhancing the efficacy of anti-cancer drugs, reducing their toxicity to normal cells and overcoming drug resistance.(43) NDDSs can general…”
BackgroundReview of computer simulations on anti-cancer drug delivery in MOFs
Kotzabasaki, M. I., & Froudakis, G. E. (2018) · Inorganic Chemistry Frontiers · doi:10.1039/c7qi00645d · Cited by 109
Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases
Anderson, C. F., Grimmett, M. E., Domalewski, C. J., & Cui, H. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1586 · Cited by 112
Feng, X., Lin, T., Chen, D., Li, Z., Yang, Q., Tian, H., Xiao, Y., Lin, M., Liang, M., Guo, W., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.02.011 · Cited by 111
Nanotechnology in drug and gene delivery
Hamimed, S., Jabberi, M., & Chatti, A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02245-z · Cited by 116
Gao, Y., Li, J., Wang, Q., Hu, H., Zhao, X., Chen, D., & Qiao, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b02016 · Cited by 110
Sikorski, A. F., Toporkiewicz, M., Meissner, J. M., Matusewicz, L., & Czogalla, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s74514 · Cited by 104
Saneja, A., Kumar, R., Mintoo, M. J., Dubey, R. D., Sangwan, P. L., Mondhe, D. M., Panda, A. K., & Gupta, P. N. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.01.026 · Cited by 104
Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives
Jing, Z., Du, Q., Zhang, X., & Zhang, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137147 · Cited by 108
Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines
Li, M., Zhang, Y., Zhang, Q., & Li, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100364 · Cited by 111
Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration
Wang, J., Ni, Q., Wang, Y., Zhang, Y., He, H., Gao, D., Ma, X., & Liang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.045 · Cited by 103
Zhang, X., Liu, L., Tang, M., Li, H., Guo, X. Q., & Yang, X. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1776320 · Cited by 102
“Research has shown that exosomal carriers have advantages over both cell-based and nanotechnology drug delivery systems for efficient drug transport [5].”
BackgroundWang, J., Zhao, W., Zhang, Z., Liu, X., Xie, T., Wang, L., Xue, Y., & Zhang, Y. (2024) · Advanced Materials · doi:10.1002/adma.202308915 · Cited by 104
Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery
He, H., Zhu, R., Sun, W., Cai, K., Chen, Y., & Yin, L. (2017) · Nanoscale · doi:10.1039/c7nr07677k · Cited by 99
Zhou, M., Li, L., Li, L., Lin, X., Wang, F., Li, Q., & Huang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.005 · Cited by 99
Jiang, C., Shen, F., Du, J., Fang, X., Li, X., Su, J., Wang, X., Huang, X., & Liu, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.146 · Cited by 97
Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine
Wang, Q., Atluri, K., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceuticals · doi:10.3390/ph16030433 · Cited by 104
“Polymers have been modified by including polyethylene glycol (PEG) to prevent opsonization and lengthen their circulation time, incorporating targeting ligands, and employing pH-sensitive or hypothermic polymer conjugates [55,56].”
BackgroundEffective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., Ma, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809304 · Cited by 101
“Organic nanoparticles (NPs) as drug delivery systems mainly include: lipid-based NPs (liposomes), polymer-based NPs and micelles, synthetic low-density lipoprotein (LDL), dendrimers, biodegradable polyesters, albuminbased nanovectors, realgar NPs, polysaccharide polymer, citrus lemon-derived nanovesicles (123, 125).”
BackgroundLi, J., Cheng, X., Chen, Y., He, W., Li, N., Xiong, P., & Wei, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.08.037 · Cited by 95
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95
“Novel strategies, such as nanomedicine targeting the CSC microenvironment, are also being explored [172,173].”
Background
Metadata
- Authors
- Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Ljubimova, Julia Y.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1866-1879
- ISSN
- 0169-409X (ISSN-L)
- PMC
- PMC5812459
- OpenAlex
- W2086374939
- Semantic Scholar
- 45ee9c859bb1f5d84491499a8da3d69d2e4c8976
- Cited by
- 733
- References
- 156
- Citations by year
- 2026: 23 · 2025: 44 · 2024: 56 · 2023: 50 · 2022: 66 · 2021: 63 · 2020: 68 · 2019: 73 · 2018: 66 · 2017: 67 · 2016: 75 · 2015: 59 · 2014: 22
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Advanced Drug Delivery Reviews (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA188743, R01CA123495, R01CA136841, U01CA151815)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanomedicine, chemoresistance, drug delivery, multidrug resistance, liposomes, polymer conjugates, micelles, dendrimers, carbon nanoparticles, metal nanoparticles, precision oncology, tumor genomic profiling
- MeSH terms
- Animals, Antineoplastic Agents, Clinical Trials as Topic, Drug Carriers, Humans, Neoplasms, Neoplastic Stem Cells, Drug Design, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Cell Line, Tumor, Nanomedicine, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
